It is well established that hepatic abnormalities may occur in patients with rheumatoid arthritis (RA) and other connective tissue disorders and these changes have usually been attributed to the systemic nature of the underlying disease process. Abnormalities reported include minor derangements of liver function (Movitt and Davis, 1953 ) and other abnormalities which have been related to the severity of the associated rheumatoid disease (Lefkovits and Farrow, 1955; Kendall, Cockel, Becker, and Hawkins, 1970) . Indices of hepatic derangement have included raised alkaline phosphatase/5-nucleotidase levels (Kendall and others, 1970; Kendall, Farr, Bold, and Hawkins, 1971; Cockel, Kendall, Becker, and Hawkins, 1971 ) and the detection of mitochondrial antibodies (Walker, Doniach, and Doniach, 1970; Whaley, Goudie, Williamson, Nuki, Dick, and Buchanan, 1970) .
Histological changes have been noted, such as infiltration of the portal tracts by chronic inflammatory cells (Lefkovits and Farrow, 1955; Schaller, Beckwith, and Wedgwood, 1970) and fatty change (Movitt and Davis, 1953) . In juvenile rheumatoid arthritis, hepatomegaly and derangement of liver function is well documented and hepatic histology has shown nonspecific infiltration of inflammatory cells in the portal tracts and hyperplasia of Kupffer cells (Schaller and others, 1970; Kornreich, Malouf, and Hanson, 1971) . Walker and others (1970) , in a study of thirty-five hospital patients found on screening to have mitochondrial antibodies, identified ten patients with subclinical liver disease. Of these ten patients, nine had rheumatological disorders (including two patients with RA, two with systemic lupus erythematosus, three with polyarthralgia, and one each with polymyalgia rheumatica and osteoarthrosis). Eight of these ten patients had liver biopsies which showed hepatitis of varying degree.
We report a group of thirty patients, who presented at a rheumatology clinic with symptoms relating to the locomotor system and who were found on routine clinical examination or biochemical screening to have hepatomegaly and/or abnormal routine liver function tests. Detailed hepatic investigations were performed in these patients to determine the cause and significance of these findings.
Patients and methods
Thirty patients who presented to a rheumatology clinic over a 2-year period were included in the study. The rheumatological diagnoses are summarized in Table I. A biochemical profile, which includes estimations of serum albumin, globulin, alkaline phosphatase, bilirubin, and aminotransferase (SGOT), is obtained in all new patients attending the clinic. In fourteen the clinical or biochemical evidence of liver disease wvas noted at their first visit, while in the remainder it was detected when they attended for review of their rheumatic disease. In the latter patients a biochemical profile is requested only if indicated on clinical grounds and therefore liver disease in review patients with biochemical abnormalities alone was probably undetected. Twenty patients were referred for further investigation because of the presence of both hepatomegaly and abnormal liver function tests, five because of hepatomegaly with normal liver function tests, and five because of abnormal liver function tests without hepatomegaly. In addition to the routine liver function tests listed above, 5-nucleotidase levels were estimated when indicated and the patients were screened for hepatitis B antigen (HBAg) and mitochondrial and smooth muscle antibodies. Twenty-three patients had a bromsulphalein retention test (5 mg/kg i.v. with 10 ml blood samples at 25 and 45 mins after injection of dye). A liver biopsy was obtained in twenty-one patients. Three patients had a transient disturbance of hepatic function consisting of hepatomegaly and a rise in aminotransferases which coincided with drug therapy. In two of these patients abnormal BSP retention occurred in addition to the above abnormalities. The drug responsible for the hepatic damage in these two patients was thought to be indomethacin (Cases 8 and 11). The other patient had raised alkaline phosphatase with 5-nucleotidase in addition to raised aminotransferases and hepatomegaly which occurred in relation to azathioprine therapy for giant cell arteritis (Case 29). In all three patients withdrawal of these drugs was followed by rapid resolution of the biochemical abnormalities, and in the two patients with indomethacin toxicity the liver size returned to normal.
CHRONIC PERSISTENT HEPATITIS
Three patients had chronic persistent hepatitis, of whom two had systemic lupus erythematosus (Cases 26 and 28). The other patient (Case 14), a 51-yearold woman, presented with a nonspecific arthralgia. Examination showed hepatomegaly and multiple spider naevi, and further investigation showed abnormal BSP retention, a positive HBAg test, and liver biopsy confirmed a chronic persistent hepatitis. She has received no therapy and on follow-up for 2 years has remained repeatedly HBAg positive with no evidence of clinical or histological progression of the disease.
CHRONIC ACTIVE HEPATITIS
Two patients had chronic active hepatitis, confirmed by liver biopsy. Both were HBAg negative. One (Case 5) had a nonspecific polyarthralgia as a presenting symptom and routine clinical examination revealed hepatomegaly. Prednisolone therapy induced diabetes mellitus but subsequently azathioprine and prednisolone in low dosage has maintained satisfactory control of his hepatic disease. The other patient (Case 25) had a 4-year history of seropositive rheumatoid arthritis and was found to have hepatomegaly. Biochemical abnormalities included a high serum globulin (4 9 g/100 ml, raised a2-and y-globulin on electrophoresis), raised alkaline phosphatase, 5-nucleotidase, and SGOT, and prothrombin activity 65 %. BSP retention was within normal limits but a liver biopsy showed chronic aggressive hepatitis with regeneration nodules and portal tract fibrosis. After prednisolone and azathioprine therapy the liver function tests have returned to normal. (Fig. 2) . These appearances were considered to be consistent with a diagnosis of polyarteritis nodosa. One patient with a seronegative polyarthritis was found to have severe fatty change (Case 9), and another patient with seropositive RA had disturbances of hepatic function and hepatomegaly due to cardiac cirrhosis, secondary to mitral valve disease (Case 16).
In ten patients no definite hepatic diagnosis was reached to explain the hepatic abnormalities. In this group five patients had had liver biopsies. One of these biopsies was normal and the others showed minor nonspecific changes including slight lymphocytic infiltration of the portal tracts (3 biopsies), fatty change (1 biopsy), and small foci of polymorphs in lobules and sinusoids (1 biopsy). Eight of these patients had hepatomegaly, seven had a raised alkaline phosphatase/5-nucleotidase, three had raised aminotransferases, and six had abnormal BSP retention.
Discussion
The detailed investigation of these thirty patients has revealed varied hepatic pathology. In twenty of them a definitive diagnosis, not previously suspected, was reached. Three patients were shown to have disturbances of liver function attributable to drug therapy (indomethacin or azathioprine) which resolved when the drugs were withdrawn, illustrating the importance of drug toxicity as a cause of liver abnormalities in patients with rheumatological disorders. Many of the drugs used in the treatment of rheumatoid arthritis and related conditions are potentially hepatotoxic. Salicylate therapy has been shown to cause raised serum transaminases (Russell, Sturge, and Smith, 1971; Rich and Johnson, 1973) . These authors found that the abnormalities were dose related and reduction of salicylate dosage led to a fall in transaminases. Two of the six patients described by Rich and Johnson had liver biopsies which showed round cell infiltration of the portal tracts in both and single cell necrosis in the parenchyma in one. Some of our patients in whom no diagnosis was reached had similar histological changes to these. Toxic hepatitis has also been described in association with indomethacin (Fenech, Bannister, and Grech, 1967; Kelsey and Scharyj, 1967) , phenylbutazone (Engleman, Krupp, Rinehart, Jones, and Gibson, 1954; Schenker, Olson, Dunn, Breen, and Combes, 1973) , gold (Schenker and others, 1973) , and azathioprine (Meyler and Herxheimer, 1972) . Drug toxicity may have been a contributory factor in some of the ten patients in whom no other cause could be found for their hepatic dysfunction.
Polyarteritis nodosa was diagnosed on the liver biopsy of the patient with Felty's syndrome who also had lymphocytic infiltration of the portal tracts. Blendis, Ansell, Jones, Hamilton, and Williams (1970) studied liver function and histology in twelve patients with Felty's syndrome and showed that lymphocytic infiltration of the portal tracts and sinusoids was the predominant histological abnormality. It is uncertain whether these findings are specific to Felty's syndrome or are merely part of the rheumatoid process. The detection of polyarteritis nodosa in our patient was unexpected, although the association of polyarteritis nodosa with seropositive rheumatoid arthritis has long been recognized (Ball, 1954 ). An association between polyarteritis nodosa and the hepatitis B antigen has also been reported (Gocke, Hsu, Morgan, Bombardieri, Lockshin, and Christian, 1970) , but this antigen was not detected in our patient.
MacKay, Taft, and Cowling (1959) have described hepatic abnormalities in systemic lupus erythematosus. They studied nineteen patients, noting hepatomegaly in nine and minor nonspecific histological changes in eleven. Liver biopsies were obtained in four of our five patients with systemic lupus erythematosus and two of these showed chronic persistent hepatitis. One biopsy was normal and in the other mild lymphocytic infiltration of the portal tracts occurred. In the latter the changes were similar to those described by MacKay and others (1959) and Dubois (1966) in patients with systemic lupus erythematosus. Although uncommon, chronic active hepatitis has been reported in association with systemic lupus erythematosus (MacKay and others, 1959) .
In three patients, hepatic dysfunction was associated with excessive alcohol intake. Only one patient had clinical evidence of gout, although all three patients had hyperuricaemia as well as hypercholesterolaemia. After restriction of alcohol, hepatic function returned to normal, uric acid levels fell to within normal limits, and the serum cholesterol levels were reduced in all three patients. Alcohol-induced hyperuricaemia and hyperlipidaemia has been well documented (Lieber, 1965; Chait, Mancini, February, and Lewis, 1972) .
In patients with known liver disease arthralgia is recognized as a not uncommon symptom and has been described in chronic active hepatitis, acute viral hepatitis, and alcoholic cirrhosis (Whelton, 1970) . A true arthritis is uncommon, although recently a painless erosive arthritis was described in a patient with chronic active hepatitis (Barnardo, VernonRoberts, and Currey, 1973) . Although the arthropathy usually occurs after the liver disease has declared itself, it may precede clinical evidence of liver disease (Whelton, 1970) . The four patients who presented with polyarthralgia were all found to have a specific hepatic disorder, the diagnoses including chronic active hepatitis, chronic persistent hepatitis, alcoholic liver disease, and sarcoidosis.
Arthropathy is a common clinical feature of idiopathic haemochromatosis (Schumacher, 1964; Dymock, Hamilton, Laws, and Williams, 1970) , but no evidence of this condition was found in the two patients in whom increased iron deposition was shown histologically and the degree of iron deposition did not approach that found in idiopathic haemochromatosis. Both these patients had long-standing rheumatological disorders (seropositive rheumatoid arthritis in one patient and psoriatic arthropathy in the other) and had received prolonged iron therapy.
In several of the patients described in this series, the occurrence of hepatic disease in association with a rheumatological disorder must be fortuitous. Examples include the patients with chronic active hepatitis and primary biliary cirrhosis who had long-standing seropositive rheumatoid arthritis. Such associations may simply reflect the well-known increased susceptibility of patients with one disease associated with abnormalities ofimmune mechanisms to develop autoimmune disturbances involving other systems.
In conclusion, our results suggest that detailed hepatic investigations, including liver biopsy if indicated, are justified in patients with rheumatic disorders who have hepatomegaly and/or abnormal routine liver function tests. It should not be assumed that these abnormalities are due to liver involvement as part of a multisystem autoimmune disease, as a variety of subclinical liver diseases may be revealed, some of which may be treatable or reversible. In particular, the importance of drug therapy as a cause of hepatic dysfunction in these patients must be emphasized.
Summary
The results of detailed hepatic investigations are reported in thirty patients who presented to a rheumatology clinic with joint symptoms, and who were found on routine clinical examination or biochemical screening to have hepatomegaly and/or abnormal routine liver function tests. In twenty patients a specific hepatic disorder was found and a varied spectrum of liver disease revealed. The diagnoses included alcoholic liver disease (three patients), drug-induced liver damage (three patients), primary biliary cirrhosis (three patients), chronic persistent hepatitis (three patients), chronic active hepatitis (two patients), polyarteritis nodosa, sarcoidosis, cardiac cirrhosis, and severe fatty change (one patient each). 
